mRNA Therapeutics CDMO Market Projected to Reach $8.14 Billion by 2030

The mRNA Therapeutics CDMO market is forecasted to hit $8.14 billion by 2030, growing at an 11% CAGR. North America, led by the USA, will be the largest regional market. Manufacturing services, infectious diseases, viral vaccines, and biotechnology companies are identified as the leading segments. Key growth drivers include the expanding mRNA therapeutics pipeline, increased biopharma outsourcing, and technological advancements in manufacturing platforms, creating substantial opportunities across various service areas.

The mRNA Therapeutics CDMO market is set for significant expansion, projected to reach $8.14 billion by 2030 with an impressive compound annual growth rate (CAGR) of 11%. This market will represent approximately 3% of the broader Pharmaceutical CDMO market and 0.3% of the overall Pharmaceuticals industry by that year. Geographically, North America is anticipated to dominate, accounting for $2.9 billion of the market value, with the USA leading as the largest country at $2.7 billion, driven by robust investments and a supportive regulatory environment.Manufacturing services are expected to be the largest segment by type of service, contributing $4 billion, while infectious diseases will lead by indication with $3 billion. In terms of application, viral vaccines will form the largest segment, also valued at $3 billion, due to rising demand for rapid-response vaccine development. Biotechnology companies are forecasted to be the primary end-users, capturing $6 billion of the market, driven by their increasing need for outsourced development and manufacturing.Growth will be fueled by three major factors: the global expansion of the mRNA therapeutics pipeline, increasing outsourcing by biopharmaceutical companies seeking to reduce capital investment and accelerate timelines, and continuous technological advancements in mRNA manufacturing platforms. Significant growth opportunities are identified across development, manufacturing, and laboratory services, collectively expected to add over $3.4 billion in market value by 2030, reflecting a concentrated focus on rapid therapeutic development and specialized technical expertise.